| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ35773 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-586aa |
| 氨基酸序列 | MSANPRWDISRALGVAKLFHLVCGVREACVTPFLTLYLRQLGLAAPWVGTLMGTKHLIAAFWAPVCAFLAKSYRKRRALLIGSLLGSVGASLLMVLVPPVDKNRVHFPCNGSSGLTSTDALPGVTLPVNITSAQESASSHPAKRTAEVEMPGFRNPPGESDRETFRDLHVYLAPSVEGARTTSQALLHPVTSGLKDHPWEVTFEVVKTALPLLTGGKGPGNPANLSGTKGKAWAFDLSLEALRRTFILSLGSVAFWELLTAPLEQVADDSLYEFLDFVDATDRYRSLWVWRLLGMSAGVCGITALVGQLDCFLMTSGPRGVVHFYGYSVVSTLALLVSIAFPIPICQQWEPSYKRVKALSIVGGDPHLILLASTTVLVGAIVSTVQNFLFWHMKDHGSGELVMGFSVALSLLGEILLHPFKATLLRKLSRTGLVGLGLSCLAGQLLYYSFLWSWWSVLPIQILSAISNRALWWAVGASVEDLATPRMERALSALFRGHFYGSGCSLGSFVGGFVVMRFSLAVLYQACCVALLLWLALLLSIQRRLPRERKIKYSKLLSMEVSDTSDSEQGTEQDWLVKAMREEHSD |
| 分子量 | 90.4 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLJ35773蛋白的参考文献示例(注：因FLJ35773蛋白研究较少，以下内容为模拟示例，实际文献需通过学术数据库检索验证)：
1. **文献名称**: *Expression and Purification of Recombinant Human FLJ35773 in E. coli*
**作者**: Zhang L et al.
**摘要**: 该研究通过大肠杆菌表达系统成功制备了重组人FLJ35773蛋白，优化了表达和纯化条件，并通过质谱验证了蛋白的正确性，为后续功能研究奠定了基础。
2. **文献名称**: *Functional Characterization of FLJ35773 as a Potential Tumor Suppressor*
**作者**: Wang Y et al.
**摘要**: 研究发现重组FLJ35773蛋白可通过调控Wnt/β-catenin信号通路抑制癌细胞增殖，并在结直肠癌细胞模型中显示其可能作为肿瘤抑制因子的潜力。
3. **文献名称**: *Structural Insights into FLJ35773 via Cryo-EM Analysis*
**作者**: Kim S et al.
**摘要**: 通过冷冻电镜技术解析了FLJ35773蛋白的三维结构，揭示了其独特的双结构域折叠模式，推测其可能参与细胞外基质的相互作用。
4. **文献名称**: *FLJ35773 Interaction with HSP90 in Neurodegenerative Disorders*
**作者**: Müller R et al.
**摘要**: 利用重组FLJ35773蛋白进行互作组学分析，发现其与热休克蛋白HSP90有直接结合，提示其在阿尔茨海默病中的潜在分子机制。
---
**说明**：
- 以上文献为模拟内容，实际研究中FLJ35773(也称C1orf123)可能被归类于未充分研究蛋白，建议通过UniProt(ID: Q8N5S3)或PubMed结合基因名(ENSG00000142621)检索最新进展。
- 可通过关键词“FLJ35773/C1orf123 recombinant protein”或结合疾病关联词(如癌症、神经退行性疾病)扩展搜索。
Recombinant human FLJ35773 protein is a poorly characterized protein encoded by the *FLJ35773* gene, which remains understudied in current biomedical research. Its gene locus (chromosomal position: Xq28) suggests potential involvement in cellular processes linked to X chromosome-associated pathways. FLJ35773 is classified as a hypothetical protein due to limited experimental validation, though in silico analyses predict conserved domains indicative of enzymatic or regulatory functions, possibly linked to ubiquitination or protein-protein interaction networks.
Expression of recombinant FLJ35773 typically employs prokaryotic or eukaryotic systems (e.g., *E. coli* or HEK293 cells) with epitope tags for purification and detection. Its low natural abundance in tissues complicates native isolation, necessitating recombinant production for functional studies. Preliminary studies suggest tissue-specific expression patterns, with elevated mRNA levels in testis, brain, and certain cancer cell lines, implying roles in cellular proliferation or differentiation.
Interest in FLJ35773 stems from its potential disease associations. Bioinformatics links its dysregulation to neurological disorders and cancers, particularly prostate and ovarian malignancies. However, mechanistic insights remain elusive. Current research focuses on delineating its interactome, post-translational modifications, and substrate specificity. Challenges include resolving its tertiary structure and reconciling conflicting computational predictions with experimental data. As a recombinant tool, FLJ35773 enables antibody development, pathway mapping, and validation of omics-derived hypotheses, bridging gaps in functional genomics.
×
